References
-
1
Feinstein S B, Heidenreich P A, Dick C D et al.
Albunex: a new intravascular ultrasound contrast agent: preliminary safety and efficacy results.
Circulation.
1988;
78
565
-
2
Gramiak R, Shah P M.
Echocardiography of the aortic root.
Invest Radiol.
1968;
3
356-366
-
3
Albrecht T, Blomley M, Bolondi L et al.
Guidelines for the use of contrast agents in ultrasound. January 2004.
Ultraschall in Med.
2004;
25
249-256
-
4
Claudon M, Cosgrove D, Albrecht T et al.
Guidelines and good clinical practice recommendations for contrast enhanced ultrasound (CEUS) – update 2008.
Ultraschall in Med.
2008;
29
28-44
-
5
Serafin-Król M, Król R, Jedrzejczyk M et al.
Potential value of contrast-enhanced gray-scale ultrasonography in diagnosis of acute muscle injury – preliminary results.
Ortop Traumatol Rehabil.
2008;
10
131-136
-
6
Kumar P, Domjan J, Bhandari P et al.
Is there an association between intestinal perfusion and Crohn’s disease activity? A feasibility study using contrast-enhanced ultrasound.
Br J Radiol.
2009;
82
112-117
-
7
Dietrich C F, Ignee A, Barreiros A P et al.
Contrast-Enhanced Ultrasound for Imaging of Adrenal Masses.
Ultraschall in Med.
2009;
. [Epub ahead of print]
-
8
Zhao H, Xu R, Ouyang Q et al.
Contrast-enhanced ultrasound is helpful in the differentiation of malignant and benign breast lesions.
Eur J Radiol.
2010;
73
288-293
-
9
Fischer T, Paschen C F, Slowinski T et al.
Differentiation of parotid gland tumors with contrast-enhanced ultrasound.
Fortschr Röntgenstr.
2010;
182
155-162
-
10
Valentino M, Galloni S S, Rimondi M R et al.
Contrast-enhanced ultrasound in non-operative management of pancreatic injury in childhood.
Pediatr Radiol.
2006;
36
558-560
-
11
Thorelius L.
Emergency real-time contrast-enhanced ultrasonography for detection of solid organ injuries.
Eur Radiol.
2007;
17
F107-F111
-
12
Valentino M, Serra C, Pavlica P et al.
Blunt abdominal trauma: diagnostic performance of contrast-enhanced US in children – initial experience.
Radiology.
2008;
246
903-909
-
13
Seitz K.
Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma and liver metastases.
Ultraschall in Med.
2005;
26
267-269
-
14
Seitz K, Bernatik T, Strobel D et al.
Contrast-enhanced ultrasound (CEUS) for the characterization of focal liver lesions in clinical practice (DEGUM Multicenter Trial): CEUS vs. MRI – a prospective comparison in 269 patients.
Ultraschall in Med.
2010;
31
492-499
-
15
Strobel D, Seitz K, Blank W et al.
Tumor-specific vascularization pattern of liver metastasis, hepatocellular carcinoma, hemangioma and focal nodular hyperplasia in the differential diagnosis of 1,349 liver lesions in contrast-enhanced ultrasound (CEUS).
Ultraschall in Med.
2009;
30
376-382
-
16
Seitz K, Strobel D, Bernatik T et al.
Contrast-Enhanced Ultrasound (CEUS) for the characterization of focal liver lesions – prospective comparison in clinical practice: CEUS vs. CT (DEGUM multicenter trial). Parts of this manuscript were presented at the Ultrasound Dreiländertreffen 2008, Davos.
Ultraschall in Med.
2009;
30
383-389
-
17
Yu M, Liu Q, Song H P et al.
Clinical application of contrast-enhanced ultrasonography in diagnosis of superficial lymphadenopathy.
J Ultrasound Med.
2010;
29
735-740
-
18 Summary of product characteristics. http://www.ema.europa.eu/humandocs/PDFs/EPAR/sonovue/H-303-PI-en.pdf Accessed May 02, 2010.
-
19
Piscaglia F, Bolondi L.
Italian Society for Ultrasound in Medicine and Biology (SIUMB) Study Group on Ultrasound Contrast Agents. The safety of Sonovue in abdominal applications: retrospective analysis of 23 188 investigations.
Ultrasound Med Biol.
2006;
32
1369-1375
-
20
Neugut A, Ghatak A, Miller R.
Anaphylaxis in the United States: an investigation into its epidemiology.
Arch Intern Med.
2001;
161
2046-2047
-
21
Grayburn P A.
Product safety compromises patient safety (an unjustified black box warning on ultrasound contrast agents by the Food and Drug Administration).
Am J Cardiol.
2008;
101
892-893
-
22
Daniel W G, Erbel R, Kasper W et al.
Safety of transesophageal echocardiography. A multicenter survey of 10,419 examinations.
Circulation.
1991;
83
817-821
-
23 US Food and Drug Administration .Micro-bubble Contrast Agents (marketed as Definity (Perflutren Lipid Microsphere) Injectable Suspension and Optison (Perflutren Protein-Type A Microspheres for Injection). October/2007 http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm152686.htm Accessed May 02, 2010.
-
24
Uno K, Takenaka K, Asada K et al.
Diagnosis of subacute cardiac rupture by contrast echocardiography.
J Am Soc Echocardiogr.
2006;
19
1401.e9-1401.e11.s
-
25
Hannouche da Trindade M LZ, Tsutsui J M, Rodrigues A CT et al.
Left ventricular free wall impeding rupture in post-myocardial infarction period diagnosed by myocardial contrast echocardiography.
Cardiovasc Ultrasound.
2006;
4
7
-
26
Mansencal N, Nasr I A, Pillière R et al.
Usefulness of contrast echocardiography for assessment of left ventricular thrombus after acute myocardial infarction.
Am J Cardiol.
2007;
99
1667-1670
-
27
Gaibazzi N, Squeri A, Ardissino D et al.
Safety of contrast flash-replenishment stress echocardiography in 500 patients with a chest pain episode of undetermined origin within the last 5 days.
Eur J Echocardiogr.
2009;
10
726-732
-
28
Ascenti G, Zimbaro G, Mazziotti S et al.
Harmonic US imaging of vesicoureteric reflux in children: usefulness of a second generation US contrast agent.
Pediatr Radiol.
2004;
34
481-487
-
29
Darge K.
Voiding urosonography with ultrasound contrast agents for the diagnosis of vesicoureteric reflux in children. I. Procedure.
Pediatr Radiol.
2008;
38
40-53
1 Members of the EFSUMB Executive Bureau.
2 Chairperson of EFSUMB Committee for Medical Ultrasound Safety, efsumb@efsumb.org.
